Alle Fotos(1)

Dokumente

B3563

Bifonazol

Name: Bifonazol
Brand: SIGMA

≥98% (HPLC)

Synonym(e):

1-(p,α-Diphenylbenzyl)-imidazol

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):

C₂₂H₁₈N₂

CAS-Nummer:

60628-96-8

Molekulargewicht:

310.39

EG-Nummer:

262-336-6

MDL-Nummer:

MFCD00865567

UNSPSC-Code:

12352200

PubChem Substanz-ID:

329773219

NACRES:

NA.77

Empfohlene Produkte

Slide 1 of 10

1 of 10

Sigma-Aldrich

C6019

Clotrimazol

Sigma-Aldrich

A9878

4-Aminobenzoesäure

Sigma-Aldrich

D4628

Diethylstilbestrol

Supelco

PHR1296

Bifonazol

Supelco

PHR1015

Diphenhydramin -hydrochlorid

B1110000

Bifonazol

Sigma-Aldrich

E1501

4-Amino-benzoesäure-ethylester

Sigma-Aldrich

G9518

Gemfibrozil

Sigma-Aldrich

B1334

Benzaldehyd

Sigma-Aldrich

D3630

Diphenhydramin -hydrochlorid

Qualitätsniveau

100

Assay

≥98% (HPLC)

Form

powder

Farbe

white to off-white

Löslichkeit

DMSO: >10 mg/mL

Ersteller

Bayer

Lagertemp.

room temp

SMILES String

c1ccc(cc1)C(c2ccc(cc2)-c3ccccc3)n4ccnc4

InChI

1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H

InChIKey

OCAPBUJLXMYKEJ-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Biochem./physiol. Wirkung

Bifonazol ein Imidazol-basiertes Antipilzmittel mit einem breiten Wirkspektrum gegen viele Pilze, Schimmel, Hefen und einige Gram-positive Bakterien. Bifonazol hemmt Ergosterol Biosynthetic Protein 28 und Cytochrom P450 2B4.

Bifonazole is used to treat several infections such as onychomycoses, otomycoses, erythrasma, psoriasis, sebopsoriasis, seborrhoeic dermatitis and rosacea. Bifonazole is also used as an important drug to treat melanoma.

Leistungsmerkmale und Vorteile

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramme

GHS07

Signalwort

Warning

H-Sätze

H302

P-Sätze

P264 - P270 - P301 + P312 - P501

Gefahreneinstufungen

Acute Tox. 4 Oral

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells

Penso J and Beitner R

European Journal of Pharmacology, 342(1), 113-117 (1998)

Sai Hu et al.

International journal of molecular medicine, 47(5) (2021-03-12)

Radioresistance is the predominant cause for radiotherapy failure and disease progression, resulting in increased breast cancer‑associated mortality. Using gene expression signature analysis of the Library of Integrated Network‑Based Cellular Signatures (LINCS) and Gene Expression Omnibus (GEO), the aim of the

A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis.

Shinichi Watanabe et al.

Mycoses, 49(3), 236-241 (2006-05-10)

The aim of the study was to compare the efficacy and safety of luliconazole 1% cream and bifonazole 1% cream as applied in the treatment of tinea pedis (interdigital-type and plantar-type). A multi-clinic, randomised single-blind, parallel group study with 34

Association of high-dose bifonazole administration during early pregnancy and severe limb reduction defects in the newborn.

Nehama Linder et al.

Birth defects research. Part A, Clinical and molecular teratology, 88(3), 201-204 (2009-12-17)

Neonatal limb reduction defects may be caused by exposure to an external agent. The azole derivatives are used in the treatment of systemic and dermal mycoses. Their relative teratogenic risk is still controversial. We describe two newborns with severe limb

Investigation by site-directed mutagenesis of the role of cytochrome P450 2B4 non-active-site residues in protein-ligand interactions based on crystal structures of the ligand-bound enzyme.

P Ross Wilderman et al.

The FEBS journal, 279(9), 1607-1620 (2011-11-05)

Residues located outside the active site of cytochromes P450 2B have exhibited importance in ligand binding, structural stability and drug metabolism. However, contributions of non-active-site residues to the plasticity of these enzymes are not known. Thus, a systematic investigation was

Alle zugehörigen Dokumente anzeigen

Dokumente

Bifonazol

≥98% (HPLC)

About This Item

Empfohlene Produkte

Eigenschaften

Qualitätsniveau

Assay

Form

Farbe

Löslichkeit

Ersteller

Lagertemp.

SMILES String

InChI

InChIKey

Beschreibung

Biochem./physiol. Wirkung

Leistungsmerkmale und Vorteile

Sicherheitshinweise

Piktogramme

Signalwort

H-Sätze

P-Sätze

Gefahreneinstufungen

Lagerklassenschlüssel

WGK

Flammpunkt (°F)

Flammpunkt (°C)

Dokumentation

Analysenzertifikate (COA)

Besitzen Sie dieses Produkt bereits?

Peer-Reviewed-Artikel

Protokolle und Artikel

Verwandter Inhalt

Technischer Dienst